High-throughput sequencing of archival cerebrospinal fluid specimens defines B-lymphoblastic leukemia clonal composition
Karl Foley
University of Rochester School of Medicine & Dentistry, Rochester, New York, USA
Search for more papers by this authorDiana G. Adlowitz
Division of Hematology/Oncology, Department of Pediatrics, University of Rochester, Rochester, New York, USA
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorCameron Baker
Department of Biostatistics and Computational Biology, Genomics Research Center, University of Rochester, Rochester, New York, USA
Search for more papers by this authorPhilip J. Rock
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorRichard Burack
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorCorresponding Author
Carol Fries
Division of Hematology/Oncology, Department of Pediatrics, University of Rochester, Rochester, New York, USA
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Correspondence
Carol Fries, Division of Hematology/Oncology, Department of Pediatrics, 601 Elmwood Ave, Rochester, NY 14642, USA.
Email: [email protected]
Search for more papers by this authorKarl Foley
University of Rochester School of Medicine & Dentistry, Rochester, New York, USA
Search for more papers by this authorDiana G. Adlowitz
Division of Hematology/Oncology, Department of Pediatrics, University of Rochester, Rochester, New York, USA
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorCameron Baker
Department of Biostatistics and Computational Biology, Genomics Research Center, University of Rochester, Rochester, New York, USA
Search for more papers by this authorPhilip J. Rock
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorRichard Burack
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Search for more papers by this authorCorresponding Author
Carol Fries
Division of Hematology/Oncology, Department of Pediatrics, University of Rochester, Rochester, New York, USA
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York, USA
Correspondence
Carol Fries, Division of Hematology/Oncology, Department of Pediatrics, 601 Elmwood Ave, Rochester, NY 14642, USA.
Email: [email protected]
Search for more papers by this authorAbstract
Detailed characterization of the B-lymphoblastic leukemia (B-ALL) cells which invade the central nervous system (CNS) has been limited by practical challenges. To test whether the clonal composition of the cerebrospinal fluid (CSF) reflects the primary B-ALL tissue, we applied immunoglobulin (Ig) high-throughput sequencing (HTS) of archival CSF cytospin preparations from six patients with morphologically defined CNS involvement. We discovered that most CSF clones are detectable at some timepoint in the primary tissue, but that shifting clonal abundance is prevalent across tissue sites between diagnosis and relapse. Ig HTS of CSF cytospins may improve understanding of sanctuary site dissemination in B-ALL.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The IgH sequencing data that support the findings of this study are openly available in NCBI Sequence Read Archive (SRA) at https://submit.ncbi.nlm.nih.gov/subs/sra/SUB13935342/overview, reference number UB13935342.
Supporting Information
| Filename | Description |
|---|---|
| pbc31281-sup-0001-SuppMat.pdf2 MB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Richards S, Pui CH, Gayon P. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60(2): 185-195. doi:10.1002/pbc.24228
- 2Duffner PK, Armstrong FD, Chen L, et al. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2014; 36(1): 8-15. doi:10.1097/mph.0000000000000000
- 3Bartram J, Goulden N, Wright G, et al. High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments. Haematologica. 2018; 103(3): e110-e114. doi:10.3324/haematol.2017.174987
- 4Thastrup M, Duguid A, Mirian C, Schmiegelow K, Halsey C. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022; 36(12): 2751-2768. doi:10.1038/s41375-022-01714-x
- 5Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018; 131(12): 1350-1359. doi:10.1182/blood-2017-09-806521
- 6Fries C, Adlowitz DG, Spence JM, Spence JP, Rock PJ, Burack WR. Acute lymphoblastic leukemia clonal distribution between bone marrow and peripheral blood. Pediatr Blood Cancer. 2020; 67(6):e28280. doi:10.1002/pbc.28280
- 7Gawad C, Pepin F, Carlton VE, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012; 120(22): 4407-4417. doi:10.1182/blood-2012-05-429811
- 8Fries C, Lee LW, Devidas M, et al. Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. Haematologica. 2023; 108(3): 900-904. doi:10.3324/haematol.2022.281146
- 9Wu J, Jia S, Wang C, et al. Minimal residual disease detection and evolved IGH clones analysis in acute B lymphoblastic leukemia using IGH deep sequencing. Front Immunol. 2016; 7: 403. doi:10.3389/fimmu.2016.00403
- 10Bashford-Rogers RJ, Nicolaou KA, Bartram J, et al. Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. Leukemia. 2016; 30(12): 2312-2321. doi:10.1038/leu.2016.142
- 11Tang J, Yu J, Cai J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood. 2021; 138(4):331-343. doi:10.1182/blood.2020010438
10.1182/blood.2020010438 Google Scholar
- 12Levinsen M, Marquart HV, Groth-Pedersen L, et al. Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases. Pediatr Blood Cancer. 2016; 63(11): 1935-1942. doi:10.1002/pbc.26128
- 13Popov A, Henze G, Verzhbitskaya T, et al. Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. J Cancer Res Clin Oncol. 2019; 145(5): 1331-1339. doi:10.1007/s00432-019-02886-3
- 14Sayed D, Badrawy H, Ali AM, Shaker S. Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leuk Res. 2009; 33(5): 655-661. doi:10.1016/j.leukres.2008.09.033
- 15Hug A, Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, Goldschmidt H, Wildemann B. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J Neurol Sci. 2004; 219(1-2): 83-88. doi:10.1016/j.jns.2003.12.012
- 16Olszewski AJ, Chorzalska AD, Petersen M, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021; 5(24): 5525-5535. doi:10.1182/bloodadvances.2021004512
- 17Sampathi S, Chernyavskaya Y, Haney MG, et al. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Front Oncol. 2022; 12:958673. doi:10.3389/fonc.2022.958673
- 18Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood. 2017; 130(4): 440-452. doi:10.1182/blood-2017-03-735639
- 19Hicks C, Sitthi-Amorn J, Douglas J, et al. Molecular analysis of central nervous system disease spectrum in childhood acute lymphoblastic leukemia. Clin Med Insights Oncol. 2016; 10: 5-15. doi:10.4137/cmo.S18180
- 20Vanner RJ, Dobson SM, Gan OI, et al. Multiomic profiling of central nervous system leukemia identifies mRNA translation as a therapeutic target. Blood Cancer Discov. 2022; 3(1): 16-31. doi:10.1158/2643-3230.Bcd-20-0216
- 21van der Velden VH, de Launaij D, de Vries JF, et al. New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2016; 172(5): 769-781. doi:10.1111/bjh.13887
